中药复方通心络与急性心肌梗死患者的临床结局:CTS-AMI随机临床试验
通心络是一种中药复方,在体外、动物和小型人体研究中显示出对心肌梗死的潜力,但尚未在大型随机临床试验中严格评估。本研究为随机、双盲、安慰剂对照临床试验,在中国124家医院纳入症状发作24小时内的ST段抬高型心肌梗死(STEMI)患者,随机1:1接受通心络或安慰剂口服12个月,主要终点为30天主要不良心脑血管事件(MACCE)。结果显示通心络组30天MACCE发生率显著低于安慰剂组(3.4% vs 5.2%;RR 0.64,95%CI 0.47-0.88),1年MACCE发生率亦持续较低(5.3% vs 8.3%;HR 0.64,95%CI 0.49-0.82)。
要点
- 通心络组30天MACCE发生率3.4% vs 安慰剂组5.2%(RR 0.64,95%CI 0.47-0.88)。
- 通心络组1年MACCE发生率5.3% vs 安慰剂组8.3%(HR 0.64,95%CI 0.49-0.82)。
- 通心络组不良反应发生率2.1% vs 安慰剂组1.1%(P=0.02),主要为胃肠道症状。
核心结论
- 在STEMI患者中,中成药通心络作为STEMI指南导向治疗的辅助治疗,显著改善了30天和1年临床结局。
- 需要进一步研究以确定通心络在STEMI中的作用机制。
研究设计与样本
- 随机、双盲、安慰剂对照临床试验,在中国124家医院纳入症状发作24小时内的STEMI患者。
- 患者于2019年5月至2020年12月入组,末次随访日期为2021年12月15日。
- 共随机3797例患者,其中3777例纳入主要分析(通心络组1889例,安慰剂组1888例;平均年龄61岁;男性76.9%)。
- 患者按1:1随机接受通心络或安慰剂口服12个月(随机化后给予负荷剂量2.08 g,随后维持剂量1.04 g,每日3次),并在STEMI指南导向治疗基础上给药。
- 主要终点为30天主要不良心脑血管事件(MACCE),包括心源性死亡、心肌再梗死、急诊冠状动脉血运重建和卒中的复合终点;MACCE随访每3个月一次至1年。
主要发现
- 30天MACCE发生于通心络组64例(3.4%)vs 对照组99例(5.2%)(RR 0.64,95%CI 0.47-0.88;RD -1.8%,95%CI -3.2%至-0.6%)。
- 30天MACCE的单个组分中心源性死亡在通心络组亦显著低于安慰剂组(56例[3.0%] vs 80例[4.2%];RR 0.70,95%CI 0.50-0.99;RD -1.2%,95%CI -2.5%至-0.1%)。
- 至1年时,通心络组MACCE发生率持续较低(100例[5.3%] vs 157例[8.3%];HR 0.64,95%CI 0.49-0.82;RD -3.0%,95%CI -4.6%至-1.4%)。
- 至1年时,通心络组心源性死亡发生率亦较低(85例[4.5%] vs 116例[6.1%];HR 0.73,95%CI 0.55-0.97;RD -1.6%,95%CI -3.1%至-0.2%)。
- 其他次要终点包括30天卒中、30天和1年大出血、1年全因死亡率及支架内血栓(<24小时;1-30天;1-12个月)均无显著差异;通心络组不良反应发生率高于安慰剂组(40例[2.1%] vs 21例[1.1%];P=0.02),主要归因于胃肠道症状。
临床怎么用
- 在STEMI指南导向治疗基础上,通心络作为辅助治疗可能改善30天和1年临床结局。
局限性
- 需要进一步研究以确定通心络在STEMI中的作用机制。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
IMPORTANCE: Tongxinluo, a traditional Chinese medicine compound, has shown promise in in vitro, animal, and small human studies for myocardial infarction, but has not been rigorously evaluated in large randomized clinical trials. OBJECTIVE: To investigate whether Tongxinluo could improve clinical outcomes in patients with ST-segment elevation myocardial infarction (STEMI). DESIGN, SETTING, AND PARTICIPANTS: Randomized, double-blind, placebo-controlled clinical trial was conducted among patients with STEMI within 24 hours of symptom onset from 124 hospitals in China. Patients were enrolled from May 2019 to December 2020; the last date of follow-up was December 15, 2021. INTERVENTIONS: Patients were randomized 1:1 to receive either Tongxinluo or placebo orally for 12 months (a loading dose of 2.08 g after randomization, followed by the maintenance dose of 1.04 g, 3 times a day), in addition to STEMI guideline-directed treatments. MAIN OUTCOMES AND MEASURES: The primary end point was 30-day major adverse cardiac and cerebrovascular events (MACCEs), a composite of cardiac death, myocardial reinfarction, emergent coronary revascularization, and stroke. Follow-up for MACCEs occurred every 3 months to 1 year. RESULTS: Among 3797 patients who were randomized, 3777 (Tongxinluo: 1889 and placebo: 1888; mean age, 61 years; 76.9% male) were included in the primary analysis. Thirty-day MACCEs occurred in 64 patients (3.4%) in the Tongxinluo group vs 99 patients (5.2%) in the control group (relative risk [RR], 0.64 [95% CI, 0.47 to 0.88]; risk difference [RD], -1.8% [95% CI, -3.2% to -0.6%]). Individual components of 30-day MACCEs, including cardiac death (56 [3.0%] vs 80 [4.2%]; RR, 0.70 [95% CI, 0.50 to 0.99]; RD, -1.2% [95% CI, -2.5% to -0.1%]), were also significantly lower in the Tongxinluo group than the placebo group. By 1 year, the Tongxinluo group continued to have lower rates of MACCEs (100 [5.3%] vs 157 [8.3%]; HR, 0.64 [95% CI, 0.49 to 0.82]; RD, -3.0% [95% CI, -4.6% to -1.4%]) and cardiac death (85 [4.5%] vs 116 [6.1%]; HR, 0.73 [95% CI, 0.55 to 0.97]; RD, -1.6% [95% CI, -3.1% to -0.2%]). There were no significant differences in other secondary end points including 30-day stroke; major bleeding at 30 days and 1 year; 1-year all-cause mortality; and in-stent thrombosis (<24 hours; 1-30 days; 1-12 months). More adverse drug reactions occurred in the Tongxinluo group than the placebo group (40 [2.1%] vs 21 [1.1%]; P = .02), mainly driven by gastrointestinal symptoms. CONCLUSIONS AND RELEVANCE: In patients with STEMI, the Chinese patent medicine Tongxinluo, as an adjunctive therapy in addition to STEMI guideline-directed treatments, significantly improved both 30-day and 1-year clinical outcomes. Further research is needed to determine the mechanism of action of Tongxinluo in STEMI. TRIAL REGISTRATION: ClinicalTrials.gov Identifier: NCT03792035.
引用
- Yang Y, Li X, Chen G, et al. Traditional Chinese Medicine Compound (Tongxinluo) and Clinical Outcomes of Patients With Acute Myocardial Infarction: The CTS-AMI Randomized Clinical Trial. JAMA. 2023. PMID: 37874574. doi:10.1001/jama.2023.19524
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。